Featured Publications
Somatic PIK3CA Mutations in Sporadic Cerebral Cavernous Malformations
Peyre M, Miyagishima D, Bielle F, Chapon F, Sierant M, Venot Q, Lerond J, Marijon P, Abi-Jaoude S, Le Van T, Labreche K, Houlston R, Faisant M, Clémenceau S, Boch AL, Nouet A, Carpentier A, Boetto J, Louvi A, Kalamarides M. Somatic PIK3CA Mutations in Sporadic Cerebral Cavernous Malformations. New England Journal Of Medicine 2021, 385: 996-1004. PMID: 34496175, PMCID: PMC8606022, DOI: 10.1056/nejmoa2100440.Peer-Reviewed Original ResearchConceptsSporadic cerebral cavernous malformationCerebral cavernous malformationsFamilial cerebral cavernous malformationsCavernous malformationsTissue samplesSomatic PIK3CA mutationsCentral nervous systemVascular malformationsPIK3CA mutationsMouse modelHarbored mutationsNervous systemPatientsHuman meningiomasMeningiomasCommon genetic driversGenetic causeLesion tissueMalformationsFunction mutationsSomatic mutationsGenetic driversMiceReaction analysisMutations
2021
Targeting the CSF1/CSF1R axis is a potential treatment strategy for malignant meningiomas
Yeung J, Yaghoobi V, Miyagishima D, Vesely MD, Zhang T, Badri T, Nassar A, Han X, Sanmamed MF, Youngblood M, Peyre M, Kalamarides M, Rimm DL, Gunel M, Chen L. Targeting the CSF1/CSF1R axis is a potential treatment strategy for malignant meningiomas. Neuro-Oncology 2021, 23: 1922-1935. PMID: 33914067, PMCID: PMC8563319, DOI: 10.1093/neuonc/noab075.Peer-Reviewed Original ResearchConceptsColony-stimulating factor-1Myeloid cellsMalignant meningiomasTumor microenvironmentCSF1/CSF1RRNA-seqRNA sequencingHuman meningiomasImmune subsetsGene expressionT cellsTreatment strategiesNormalization cancer immunotherapyImportant regulatorCell typesNovel immunocompetent murine modelDeath ligand 1 (PD-L1) expressionCell death receptor-1Immunosuppressive myeloid cellsDeath receptor-1Ligand 1 expressionFactor 1Immune cell typesImmunocompetent murine modelEffective treatment strategies